Impetigo – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Impetigo – Pipeline Review, H2 2017’, provides an overview of the Impetigo pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Impetigo, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Impetigo and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Impetigo

The report reviews pipeline therapeutics for Impetigo by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Impetigo therapeutics and enlists all their major and minor projects

The report assesses Impetigo therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Impetigo

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Impetigo

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Impetigo pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Destiny Pharma Ltd

Foamix Pharmaceuticals Ltd

Fujifilm Holdings Corporation

Laboratories Ojer Pharma SL

Lytix Biopharma AS

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Impetigo - Overview 6

Impetigo - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 11

Impetigo - Therapeutics Assessment 12

Assessment by Target 12

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Impetigo - Companies Involved in Therapeutics Development 20

Destiny Pharma Ltd 20

Foamix Pharmaceuticals Ltd 20

Fujifilm Holdings Corporation 20

Laboratories Ojer Pharma SL 21

Lytix Biopharma AS 21

Impetigo - Drug Profiles 23

FMX-102 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

LTX-109 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

mupirocin - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

ozenoxacin - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Synthetic Peptides for Infectious Disease - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

XF-70 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Impetigo - Dormant Projects 32

Impetigo - Discontinued Products 33

Impetigo - Product Development Milestones 34

Featured News & Press Releases 34

May 08, 2017: Cipher Pharmaceuticals Receives Health Canada Approval of OZANEX (ozenoxacin cream 1%) 34

Jul 12, 2016: Cipher Pharmaceuticals announces Ozenoxacin accepted for review by Health Canada 34

Jun 27, 2016: Medimetriks Pharmaceuticals New Drug Application for Ozenoxacin Cream, 1% Accepted for Review by FDA 35

Jun 27, 2016: Medimetriks Pharmaceuticals Submits a New Drug Application to FDA for Ozenoxacin Cream, 1%, a Novel Impetigo Treatment 35

Jun 12, 2014: Medimetriks Pharmaceuticals Announces that the Second Phase III Study for Ozenoxacin has been Initiated by Ferrer 36

Jun 05, 2013: Ferrer Completes Phase III Clinical Trial Of Ozenoxacin In Adult And Pediatric Patients With Impetigo 36

Feb 22, 2013: Lytix Biopharma Enrolls First Patient In LTX-109 Phase II Proof Of Concept Infection Study 37

Oct 05, 2012: Ferrer Successfully Completes Absorption, Tolerability And Safety Study In Juveniles As Young As Two Months Of Age For New Antibacterial Compound Ozenoxacin 38

Jan 19, 2012: Ferrer Initiates Phase III Clinical Studies For Ozenoxacin In Development As Topical Treatment For Impetigo And Other Infectious Dermatological Conditions 38

Appendix 40

Methodology 40

Coverage 40

Secondary Research 40

Primary Research 40

Expert Panel Validation 40

Contact Us 40

Disclaimer 41

List of Tables

List of Tables

Number of Products under Development for Impetigo, H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products under Development by Universities/Institutes, H2 2017 9

Products under Development by Companies, H2 2017 10

Products under Development by Universities/Institutes, H2 2017 11

Number of Products by Stage and Target, H2 2017 13

Number of Products by Stage and Mechanism of Action, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 19

Impetigo – Pipeline by Destiny Pharma Ltd, H2 2017 20

Impetigo – Pipeline by Foamix Pharmaceuticals Ltd, H2 2017 20

Impetigo – Pipeline by Fujifilm Holdings Corporation, H2 2017 21

Impetigo – Pipeline by Laboratories Ojer Pharma SL, H2 2017 21

Impetigo – Pipeline by Lytix Biopharma AS, H2 2017 22

Impetigo – Dormant Projects, H2 2017 32

Impetigo – Discontinued Products, H2 2017 33

List of Figures

List of Figures

Number of Products under Development for Impetigo, H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products by Targets, H2 2017 12

Number of Products by Stage and Targets, H2 2017 12

Number of Products by Mechanism of Actions, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Routes of Administration, H2 2017 16

Number of Products by Stage and Routes of Administration, H2 2017 16

Number of Products by Molecule Types, H2 2017 18

Number of Products by Stage and Molecule Types, H2 2017 18

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports